Clinical Trial

Apixaban in Thrombocytopenia

Recruiting Early Phase 1

Summary

This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-03-14.

Trial Details

NCT Number	NCT06886516
Lead Sponsor	Rushad Patell
Conditions	Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
Enrollment	30 participants
Start Date	2025-02-28
Primary Completion	2027-07-01 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-15